Pharmacology, biochemistry, and behavior • June 30, 2026 • Lucie Ladislavová, Viera Kútná, Kristýna Mazochová et al.
Chronic microdosing of psilocin (0.05 or 0.075 mg/kg) in adult male Wistar rats over five weeks did not alter locomotor activity, depressive-like behavior, sociability, or novelty seeking, and did not increase cell proliferation in the dentate gyrus of the hippocampus. A small anxiogenic effect was detected in the Elevated Plus Maze. The findings suggest that, under this dosing schedule, psilocin microdosing produces limited behavioral effects and does not enhance hippocampal progenitor proliferation.
Journal of Psychopharmacology • June 28, 2026 • Yiğit Özaydın, Buket Canlan Ozaydin
An umbrella review of systematic reviews and meta-analyses on psychedelic microdosing (repeated low doses of LSD or psilocybin) for mood and cognitive effects found that the only statistically significant pooled result was a small decrease in cognitive control, contrary to popular claims of enhancement. Self-reported mood benefits were largely not replicated under placebo-controlled conditions, suggesting expectancy effects. Short-term tolerability was acceptable, but cardiovascular signals and long-term risks remain uncharacterized. The evidence base is limited by high overlap among primary studies and methodological heterogeneity.
Journal of Psychoactive Drugs • June 19, 2026 • Carla J. Berg, Darcey M. Mccready, Cassidy R. Loparco et al.
Among a sample of young adults with high rates of past-month cannabis use, lifetime and past-year psychedelic use were 27.7% and 11.9%, respectively, with psilocybin/amanita, MDMA, and LSD being most common. Nearly half used psychedelics only for nonmedical purposes. Of those who had ever used, 26.5% had microdosed. Older age, male sex, Black race, metropolitan residence, more depressive symptoms, and more adverse childhood events were linked to lifetime use. Microdosing was associated with not having children, more anxiety, and more adverse childhood events. Mental health symptoms and adverse childhood events were also tied to higher use motives, including expansion, mood enhancement, and symptom management.
Journal of Advances in Developmental Research • June 18, 2026 • Eric P. Rubenstein
The term 'microdosing' is often treated as a single phenomenon, but it actually describes a low-dose pattern applied across many substances with different mechanisms, effects, and risks. This conceptual review classifies psychedelic and psychedelic-adjacent substances—including classical psychedelics, dissociatives, empathogens, and natural compounds—by therapeutic plausibility, pharmacological mechanism, dose-response, perceptibility, tolerance, neuroplasticity, context, and evidence strength. The article argues that without separating these factors, microdosing research cannot yield interpretable or scientifically meaningful conclusions.
Frontiers in Pharmacology • June 3, 2026 • Burton J. Tabaac, Robin L. Carhart-Harris, Teresa Yung
Three individuals with persistent symptoms after traumatic brain injury or hypoxic-ischemic brain injury completed a six-week protocol combining a participant-directed iboga-containing microdosing regimen (using whole root bark biomass with about 3.845% ibogaine content, yielding an estimated 3.8–38.5 mg/day ibogaine equivalent) with weekly Accelerated Experiential Dynamic Psychotherapy and supportive nutraceuticals. All three showed progressive neurological recovery; two reported complete symptom remission at long-term follow-up. Participants discontinued all prescription medications and reported resolution of headaches, brain fog, fatigue, irritability, and mood swings, with a return to regular activities and renewed enthusiasm. The authors note that the findings do not establish causality or iboga-specific efficacy due to the multimodal intervention and methodological limitations.
Rand health quarterly • June 1, 2026 • M. Priest, B. Kilmer, Ben Senator et al.
Use of psychedelic substances is becoming more common in the U.S., with several states considering policies to decriminalize or legalize them for nonmedical use. Survey data on 11 psychedelic substances show that microdosing—taking a small, sub-hallucinogenic dose on a regular schedule—is a prevalent practice, especially for psilocybin, LSD, and MDMA. The findings provide new information to inform policy debates about alternatives to prohibition.
bioRxiv Preprint Server • May 5, 2026 • Povilas Tarailis, Inga Griskova-bulanova
preprint
Frequency-resolved EEG microstate analysis can detect changes in brain dynamics that broadband analysis misses. In two public datasets, psilocybin microdosing produced subtle, frequency-specific effects—reduced global field power and altered delta- and theta-band microstate parameters—without broadband spatiotemporal changes. Acute inhaled DMT caused broader alterations across broadband, delta, theta, and alpha activity, indicating more extensive reorganization. In both conditions, delta-band microstate C showed increased duration and microstate D decreased occurrence, though these overlaps should be interpreted cautiously due to differences in dose, route, and context. The findings suggest frequency-resolved analysis is useful for characterizing altered resting-state brain dynamics.
April 17, 2026 • Sara Arciniegas Ruiz, Sari Prutchi Sagiv, Hagit Eldar-finkelman
In a mouse model of fibromyalgia, repeated very low doses of LSD (lysergic acid diethylamide) that do not cause hallucinations reduced pain-related behaviors and discomfort in a sex- and route-dependent manner. Female mice receiving intraperitoneal injections showed sustained reductions in pain-related facial expressions and mechanical sensitivity. Oral dosing produced earlier but shorter-lasting effects. Male mice showed improved mechanical sensitivity and selected behavioral parameters with both administration routes. No major safety concerns were observed. The findings suggest that microdosed LSD could potentially be repositioned as a treatment for fibromyalgia by targeting both pain perception and mood-related components.
Translational Psychiatry • August 2, 2022 • Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente et al. • 130 citations
A double-blind placebo-controlled trial tested the effects of a low (0.5 g) dose of dried psilocybin mushrooms on 34 individuals beginning a microdosing protocol. The active dose produced more intense acute subjective effects than placebo, but only among participants who correctly guessed their condition. These effects coincided with reduced EEG theta-band power and preserved Lempel-Ziv broadband signal complexity. No evidence was found for enhanced well-being, creativity, or cognitive function; instead, small changes toward cognitive impairment appeared. The findings suggest that expectation, not the drug itself, accounts for many anecdotal benefits attributed to psilocybin microdosing.
Neuroscience & Biobehavioral Reviews • May 21, 2022 • Vince Polito, Paul Liknaitzky • 110 citations
A systematic review of 44 studies on microdosing psychedelics, published between 1955 and 2021, finds that laboratory studies show changes in pain perception, time perception, conscious state, and neurophysiology, while self-report studies indicate changes in cognitive processing and mental health. The studies varied widely in risk of bias. The authors argue that claims attributing microdosing effects largely to expectancy are premature and possibly wrong. They also clarify definitional inconsistencies by suggesting dose ranges for different substances and provide design suggestions for more rigorous future research.
Elife • March 2, 2021 • 192 citations
A self-blinding citizen science trial with 191 participants tested whether microdosing psychedelics produces psychological benefits beyond a placebo. All psychological outcomes improved from baseline to after the four-week dose period in the microdose group, but the placebo group also improved, and no significant between-group differences were observed. Small, significant differences in acute measures (emotional state, drug intensity, mood, energy, creativity) and post-acute anxiety appeared, but these could be explained by participants breaking blind. The findings suggest that anecdotal benefits of microdosing can be explained by the placebo effect.
Scientific Reports • January 21, 2021 • Laura Kaertner, Michael B. Steinborn, Hannes Kettner et al. • 152 citations
A prospective study of weekly psychedelic microdosing found that participants reported improved well-being, emotional stability, and reduced anxiety and depressive symptoms over four weeks. However, baseline positive expectancy scores predicted these improvements, suggesting a significant placebo response. The findings caution against overinterpreting the therapeutic value of microdosing.
Journal of Psychoactive Drugs • January 23, 2020 • Lindsay P. Cameron, Angela Nazarian, David E. Olson • 112 citations
A survey of 2,347 people found that psychedelic microdosing—taking sub-hallucinogenic doses on a chronic schedule—is relatively common, with 17% of respondents having tried it. Microdosers reported that the practice subjectively improved their mood, decreased anxiety, and enhanced memory, attention, and sociability. The most common reasons for quitting were the risks of taking an illegal substance (24.28%) and difficulty obtaining psychedelic compounds (22.63%). The findings suggest microdosing is associated with a broad range of self-reported socio-affective, cognitive, and physical outcomes.
Journal of Psychoactive Drugs • October 24, 2019 • Toby Lea, Nicole Amada, Henrik Jungaberle • 121 citations
People are self-administering very low doses of psychedelic drugs, known as microdosing, to improve mental health, wellbeing, and cognitive function, but little research has been conducted. A content analysis of Reddit discussions examined motivations, dosing practices, and perceived benefits and limitations. Motivations included managing mental health issues, improving psychosocial wellbeing, and cognitive enhancement. Self-reported benefits included cognitive and creative enhancement, reduced depression and anxiety, enhanced self-insight, improved mood, and better social interactions. Limitations included dosing problems, adverse physical effects, taking illegal substances, limited or no improvement, increased anxiety, and concerns about dependence. Standard doses in therapeutic settings show potential for treating mental health conditions, but clinical research on microdosing is needed.
Harm Reduction Journal • July 9, 2019 • Thomas Anderson, Rotem Petranker, Adam Christopher et al. • 130 citations
A mixed-methods study of an active microdosing community categorizes the experiences participants report, identifying high-potential avenues for future scientific research. The resulting taxonomy distills intervention targets from participant reports to help allocate research funding efficiently. Microdosing research complements full-dose psychedelic studies as clinical treatments and neuropharmacological mechanisms are developed. The framework aims to guide researchers and clinicians as experimental microdosing research begins in earnest.
The International Journal of Neuropsychopharmacology • May 30, 2019 • Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder et al. • 132 citations
A survey of 1,116 people who microdose psychedelics found that performance enhancement was the main motive (37%), with LSD (10 mcg) and psilocybin (0.5 g) used 2-4 times per week. Most users were unaware of their exact dose. Negative effects were mostly psychological and occurred acutely while under the influence, but the primary reason for stopping microdosing was that it was not effective. The authors call for placebo-controlled studies to quantify performance effects and assess longer-term negative effects.
Journal of psychoactive drugs • January 1, 2019 • James Fadiman, Sophia Korb • 122 citations
Taking a microdose of LSD (10 micrograms) every three days appears safe for a wide range of people. Over 18 months, more than a thousand individuals from 59 countries reported their moods daily using a standard checklist and written reports. Repeated microdoses were followed by improvements in negative moods, especially depression, and increases in positive moods. Participants also reported more energy, better work effectiveness, and improved health habits. Smaller samples described relief from migraine headaches, pre-menstrual syndromes, traumatic brain injury, shingles, and other conditions not previously linked to psychedelic use.
Psychopharmacology • October 24, 2018 • Luisa Prochazkova, Dominique P. Lippelt, Lorenza S. Colzato et al. • 181 citations
Microdosing psychedelics may enhance cognitive performance by improving the balance between cognitive persistence and flexibility, according to preliminary quantitative findings. The authors speculate that psychedelics affect cognitive metacontrol policies, optimizing this balance. However, they emphasize that future research with rigorous placebo-controlled designs is needed to confirm these initial results. The study provides support for cognitive-enhancing properties but remains preliminary.